AbbVie’s ABT-494 May Become Standard of Care in Immunology


Dec. 1 2016, Updated 11:04 a.m. ET

ABT-494 pipeline developments

AbbVie (ABBV) expects investigational therapy ABT-494, a selective Janus Kinase 1 (or JAK1) inhibitor, to become a standard of care in the immunology space, similar to Humira. The drug is currently being studied in Phase 3 trials as a treatment option for rheumatoid arthritis (or RA). AbbVie expects to release data from these trials in 2018.

ABT-494 is also being studied as a therapy for gastrointestinal disorders such as Crohn’s disease and ulcerative colitis. AbbVie anticipates data from Phase 2 trials evaluating ABT-494 as a therapy for Crohn’s disease by the first half of 2017.

The company has also begun Phase 2 trials to evaluate oral ABT-494 as a treatment option for atopic dermatitis. To know more about ABT-494, please refer to .

If ABT-494 gets regulatory approvals for all the targeted indications, it may have a positive impact on AbbVie’s share prices as well as those of the iShares Core S&P 500 (IVV). AbbVie makes up about 0.51% of IVV’s total portfolio holdings.

Article continues below advertisement

Phase 3 program

The above chart shows six pivotal studies in the Phase 3 program that’s evaluating ABT-494 as an RA therapy. The company is also testing the investigational therapy for difficult-to-treat patients who have failed to respond to a first biologic therapy.

Additional multiple durations of therapy are also being researched. The company aims to uncover patient segments that can benefit from early intervention with ABT-494. These trials have been thus designed in a manner that can help ABT-494 secure regulatory approval for a broad label.

If these trials prove to be successful, ABT-494 will enable AbbVie to pose strong competition to other RA players such as Pfizer (PFE), Novartis (NVS), and Amgen (AMGN).

In the next part of this series, we’ll analyze the long-term growth potential of investigational oncology drug Venclexta.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.